Search Results

Parallel Bio, a biotech company using the immune system to cure disease, today announced that Ari Gesher has joined as the first head of technology.

Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety

The Danish startup, whose lead candidate has parallels to Amgen’s MariTide, launches on the heels of Amgen’s Phase II data release for the drug last week.

Gyros Protein Technologies AB announced the launch of its PurePep® EasyClean Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.

Synedgen, Inc. announced it has completed IND-enabling studies for its lead candidate, MIIST305.

Auburn University is now home to the world’s first field-installed, clinically approved Terra.X 7 Tesla magnetic resonance imaging scanner — expanding the window for cutting-edge research and public use.

Parallel Bio, a biotech company unlocking the human body’s own power to cure disease, today announced the appointment of Dwight Morrow, a 17-year GSK veteran, as vice president and head of platform.

Parallel Bio, a biotech company unlocking the human body’s own power to cure disease, today unveiled $4.3 million in seed funding.

Parallel ENT & Allergy Partners has added a second state to its roster of high-quality, innovative ENT and allergy partners with the addition of Grand Rapids ENT.

magAssist Inc. attended the 2022 Critical Heart Disease Congress - International Society for Mechanical Circulatory Support Parallel Forum, where the firm shared the latest research results and technologies for the treatment of critical heart diseases with fellow cardiovascular researchers and experts, demonstrating its commitment to innovation and development in the field.